Despite efforts for improvement, the "State of the Air" report reveals concerns.

Published Date: 23 Apr 2023

Despite Improvement Efforts, the "State of the Air" Report Highlights Issues.

Read Full News

Latest News

AD109 Cuts AHI by 59.6% in Postmenopausal Women With OSA Reena Mehra, MD

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

7 Pulmonology Headlines You Missed in October

7 Pulmonology Headlines You Missed in October

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Todays Updates

Breath-Hold Does Not Improve Robotic Bronchoscopy Yield: STABLE Trial Roshen Mathew, MD, DAABIP

Among 117 patients, breath-hold ventilation did not improve strict diagnostic yield vs conventional (86.8% vs 92.2%) in robotic bronchoscopy.

Elizabeth Spurgeon, MD, on Lifestyle Interventions as an Adjunct to Epilepsy Care Isabella Ciccone, MPH, Elizabeth Spurgeon, MD

An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Biopsy Scarring and Pegcetacoplan Response in C3G, With Carla Nester, MD

Latest News

In a post hoc analysis of 2 phase 3 trials, AD109 reduced hypoxic burden by 69.8% vs 20.0% with placebo in postmenopausal women with OSA.

Q&A: Why IL-33 Matters for Mucus Plugs, Inflammation in COPD

2027 GOLD Report Update Preview: Changes in COPD Treatment, Biologics

Mucus Plug Reduction with Type 2 Biologics: Lessons for COPD

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

7 Pulmonology Headlines You Missed in October

News All Time

Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes Michael Wechsler, MD, MSc

Michael Wechsler, MD, reports 59% of patients in clinical remission with twice-yearly depemokimab at year 1 maintained it at year 2 in SWIFT/AGILE.

HCPLive Five at CHEST 2026

HCPLive Five at CHEST 2026

Experts Discuss PAH Treatment Selection and Access

Experts Discuss PAH Treatment Selection and Access

Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA Frank C. Sciurba, MD

Frank Sciurba, MD, reports tozorakimab improved E-RS:COPD scores vs placebo at week 52 in OBERON and TITANIA, including breathlessness and chest symptoms.

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Earlier PH Screening in ILD: PHINDER Data, With Parth Rali, MD

Weighing Bleeding Risk in Pulmonary Embolism, With Samantha Pettigrew, MD Samantha Pettigrew, MD

At CHEST 2026, Pettigrew reviewed STRATIFY and STORM-PE data, citing bleeding risk with low-dose alteplase and 90-day walk gains with thrombectomy.

Frespaciguat Misses 6MWD End Point in PH-COPD: Gabor Kovacs, MD, PhD Gabor Kovacs, MD, PhD

Gabor Kovacs, MD, PhD, discusses phase 2a INSIGNIA PH-COPD results for inhaled frespaciguat presented at CHEST 2026.

Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD Henrik Watz, MD, PhD

Henrik Watz, MD, discusses 104-week OBERON, TITANIA, and PROSPERO data on tozorakimab in COPD presented at CHEST 2026.

AI and Emerging Technologies in COPD Care, With Jean Bourbeau, MD Jean Bourbeau, MD

At CHEST 2026, Jean Bourbeau, MD, said AI may support COPD diagnosis, remote monitoring, and posthospital care, though most tools still need validation.

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP's Efficacy Holds as PALM-ILD Advances, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

TPIP Tolerable Over 2 Years in PH-ILD, With Colin Church, MBBS, PhD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD

Inside The New AHA/ACC Acute Pulmonary Embolism Categories

Inside The New AHA/ACC Acute Pulmonary Embolism Categories

Pair Echo With Right Heart Catheterization in PH: Anjali Vaidya, MD Anjali Vaidya, MD, FACC, FASE, FACP

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

New Trials Favor PE Intervention in Sicker Intermediate-Risk Patients Samantha Pettigrew, MD

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Recommended News For You

In leukemia, allogeneic HCT is beneficial following primary induction failure.

Promising OS at 5 Years With Chemo-Free Combo in Urothelial Cancer

Prostate cancer Q&A: Improving detection and reducing overtreatment

The Clues Hidden in Failed Prostate Cancer Trials

In Patients with Myeloma Who Postpone HSCT, Quadruplet Displays "Excellent Activity.".

The top three drugs for multiple myeloma treatment upfront are four.

Are patients with advanced cancer receiving treatment aligned with their goals?

Recommended Articles For You

Uncovering the Causes of Thrombocytosis: A Journey to Improved Health 

Oxytocin Signaling Beyond Labor: Physiology, Clinical Implications, and Emerging Therapeutic Directions 

Teaching Coagulation Pathways Through Visual Sequencing: A Comprehensive Review for Clinicians 

A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemo causes lasting physical decline in breast cancer survivors

2.

PFS in Multiple Myeloma Is Improved by Daratumumab Added to Standard Therapy.

3.

New study links air pollution with higher rates of head and neck cancer

4.

'Next Berlin Patient' Adds to Small but Growing Number of People Cured of HIV

5.

Post-Transplant Outcomes in Hodgkin Lymphoma Improved Over Time

1.

Emerging Therapies Using Targeted Antibody–Drug Conjugates Against Previously Difficult Tumor Targets

2.

Bone Marrow Regenerative Capacity and Hematologic Recovery

3.

Hemostatic Changes During Prolonged Extracorporeal Support

4.

Senescence in Cancer Therapy: Mechanisms, Clinical Relevance, and Therapeutic Implications

5.

Ex Vivo Engineered Hematopoietic Therapies for Functional Restoration of Blood-Cell Production

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Thromboprophylaxis In Medical Settings

2.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

4.

Oropharyngeal Cancer in Relation to HPV Status

5.

L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot